Incidence of XXXX in Germany.

@entity2724 @entity683 @entity1
STUDY OBJECTIVES: Following the 2009 pandemic, reports of an association between an AS03 adjuvanted H1N1 pandemic @entity683 vaccine and @entity2724 were published. Besides determining background incidence rates for @entity2724 in Germany this study aimed at investigating whether there was a change in incidence rates of @entity2724 between the pre-pandemic, pandemic, and the post-pandemic period on the population level. DESIGN: Retrospective epidemiological study on the incidence of @entity2724 with additional capture-recapture analysis. SETTING: German sleep centers. @entity1 OR @entity1 : Eligible were @entity1 with an initial diagnosis of @entity2724 (ICD10 Code G47.4) within the period from January 1, 2007 to December 31, 2011. INTERVENTIONS: None; observational study. MEASUREMENTS AND RESULTS: A total of 342 sleep centers were invited to participate in the study. Adequate and suitable data were provided by 233 sleep centers (68.1%). A total of 1,198 @entity1 with an initial diagnosis of @entity2724 within the observed period were included, of whom 106 (8.8%) were @entity1 and adolescents under the age of 18 years and 1,092 (91.2%) were adults. In @entity1 and adolescents, the age-standardized adjusted incidence rate significantly increased from 0.14/100,000 @entity1 -years in the pre-pandemic period to 0.50/100,000 @entity1 -years in the post-pandemic period (incidence density ratio, IDR 3.57; 95% CI 1.94-7.00). In adults, no significant change was detectable. This increase started in spring 2009. CONCLUSIONS: For the years 2007-2011, valid estimates for the incidence of @entity2724 in Germany were provided. In individuals under 18, the incidence rates continuously increased from spring 2009.
